SAN Sanofi

Press Release: Annual General Meeting of April 30, 2025

Press Release: Annual General Meeting of April 30, 2025

Annual General Meeting of April 30, 2025

  • Approval of the financial statements for the fiscal year 2024
  • Distribution of a cash dividend of €3.92 per share, with payment as of May 14, 2025
  • Board composition: renewal of four Directors and ratification of the cooptation of Jean-Paul Kress



Paris, April 30, 2025. The Combined General Shareholders’ Meeting of Sanofi was held on April 30, 2025, under the chairmanship of Frédéric Oudéa. All resolutions submitted to the vote were adopted by the shareholders.

The General Meeting approved the individual Company and consolidated financial statements for the fiscal year 2024 and decided on the distribution of an ordinary annual dividend of €3.92 per share. The payment of the dividend will be made on May 14, 2025.

The General Meeting also renewed Carole Ferrand, Barbara Lavernos, Emile Voest and Antoine Yver as Directors, and ratified the cooptation of Jean-Paul Kress.

The Board of Directors is now composed of 16 Directors, including two directors representing employees. It has an independence rate of 78% and a gender diversity rate of 43%. It also has 8 directors of foreign nationality, i.e. a rate of 50 %.

On the proposal of the Appointments, Governance and CSR Committee, the Board of Directors has appointed Clotilde Delbos, independent Director, as Chairwoman of the Compensation Committee.

The voting results and the videocast of the Annual General Meeting are available .

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations

Sandrine Guendoul | 25 |

Victor Rouault | 40 |

Nicolas Obrist | 55 |

Léo Le Bourhis | 81 |   

Léa Ubaldi | +33 (0)6 30 19 66 46 | 

Evan Berland | |   

Timothy Gilbert | 9 |

Investor Relations

Thomas Kudsk Larsen | 93 |

Alizé Kaisserian | 11 |

Felix Lauscher | 9 |

Keita Browne | 6 |

Nathalie Pham | 17 |

Tarik Elgoutni | 7 |

Thibaud Châtelet | 90 |  

Attachment



EN
30/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE

Press Release:  Sanofi’s Board of Directors proposes the appointment o...

Press Release:  Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director  Paris, March 5, 2026. The Board of Directors of Sanofi has decided to propose, at the next Annual General Meeting of shareholders scheduled for April 29, 2026, the appointment of Christel Heydemann as an independent director, as well as the renewal of the mandates of Christophe Babule and Jean-Paul Kress.  Patrick Kron, independent director and Chairman of the Nomination,...

 PRESS RELEASE

Communiqué de presse : Le Conseil d’administration de Sanofi propose l...

Communiqué de presse : Le Conseil d’administration de Sanofi propose la nomination de Christel Heydemann en qualité d’administratrice indépendante   Le Conseil d’administration de Sanofi propose la nomination de Christel Heydemann en qualité d’administratrice indépendante  Paris, le 5 mars 2026. Le Conseil d’administration de Sanofi a décidé de proposer, dans le cadre de la prochaine Assemblée générale des actionnaires prévue le 29 avril 2026, la nomination de Christel Heydemann en qualité d’administratrice indépendante et le renouvellement des mandats de Christophe Babule et Jean-P...

 PRESS RELEASE

Press Release: Filing of an amendment to the French “Document d’Enregi...

Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, March 4, 2026. Sanofi announces today the filing of an amendment to its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF). This amendment notably includes additions to the report on corporate governance established in accordance with French law. ...

 PRESS RELEASE

Communiqué de presse : Dépôt d’un amendement au Document d’Enregistrem...

Communiqué de presse : Dépôt d’un amendement au Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel Dépôt d’un amendement au Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel Paris, le 4 mars 2026. Sanofi annonce avoir déposé ce jour un amendement à son Document d’Enregistrement Universel 2025 contenant le Rapport Financier Annuel auprès de l’Autorité des marchés financiers (AMF) en France. Cet amendement intègre notamment des compléments au (i) rapport de gestion et au (ii) rapport sur le gouvernement d’entreprise. Le document pe...

 PRESS RELEASE

Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in...

Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RDThird global orphan drug designation for rilzabrutinib in IgG4-RD, underpinning Sanofi’s commitment to rare immune-mediated diseases Paris, March 2, 2026 – The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted orphan drug designation to rilzabrutinib, a novel, oral, reversible covalent Bruton’s tyrosine ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch